RxDoctor Payments Data

Anibal Avila, MD

Internal Medicine · Oklahoma City, OKNPI 1649213513

Payments from drug & device makers

$716in general payments, 2019–2025

Across 41 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$147
  • Novo Nordisk$147
  • AstraZeneca$108
  • Indivior Inc.$71
  • Pfizer$53
  • Lilly USA, LLC$53
  • plus $136 from 7 others

What the payments were for

  • Food & beverage$716100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim8$147
Novo Nordisk9$147
AstraZeneca6$108
Indivior Inc.4$71
Pfizer3$53
Lilly USA, LLC3$53
AbbVie2$44
Gilead1$23
Sanofi-aventis U.S. LLC1$17
Shionogi Inc1$13
Pear Therapeutics (US), Inc.1$13
Dexcom, Inc.1$13
Johnson & Johnson1$12

How this compares

$716 in reported general payments places this provider in the 60th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$19,859
Medicare patients
42
Services billed
256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$69,844
JardianceEmpagliflozin34$53,537
JanuviaSitagliptin Phosphate18$24,753
SynjardyEmpagliflozin/Metformin Hcl18$21,992
RybelsusSemaglutide15$20,365
Xtampza ErOxycodone Myristate33$18,751
JanumetSitagliptin Phos/Metformin Hcl11$18,319
EliquisApixaban15$15,132
SymbicortBudesonide/Formoterol Fumarate44$12,279
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen398$11,014
MovantikNaloxegol Oxalate19$7,765
Tresiba Flextouch U-100Insulin Degludec12$5,290
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,638
Gabapentin132$2,483
Buprenorphine Hcl65$2,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$147$90,20952 claims
Boehringer IngelheimJardiance, Synjardy$147$75,52952 claims
PfizerEliquis$53$15,13215 claims
AstraZenecaSymbicort$108$12,27944 claims
Lilly USA, LLCOlanzapine$53$42119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →